brexit_istock-531915594_altamira83

altamira83 / iStockphoto.com

30 April 2018Big Pharma

UK medicines regulator wants active EU partnership post-Brexit

An “active regulatory partnership” between the UK and the EU is necessary to ensure patients have “timely access” to medicines post-Brexit, according to the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

J&J sues over schizophrenia drug generic following patent victory

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids